Biotech 2009-Life Sciences: Navigating the Sea Change

Sea change: Noun: a striking change, as in appearance, often for the better

Biotech 2009-Life Sciences: Navigating the Sea Change is the 23rd edition of this yearly publication. It provides a compass to guide you through the current financial market turmoil. The 400-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond.

The biotech industry has had nearly 40 years of easy access to inexpensive capital. The capital markets have permanently restructured, making access to capital more difficult and expensive to access.

• Buy-side interest and resources are reduced.
• Venture capitalist and private investors no longer can rely on IPOs for exits.
• Big Pharma is not as eager to make deals. As these companies see it, technology will be cheaper to buy if they wait.
• Falling oil prices may slow the momentum for alternate fuels.

• 1. Navigating the sea change: An overview of the challenges ahead.
• 2. Industry Metrics: Burrill & Company' s critical statistics on the life sciences, presented in a clear and easy-to-use format.
• 3. Healthcare: The cost of health, trends in healthcare delivery, ideas for reform including electronic health records and personal health records, large cap biotech and pharma industry models and metrics
• 4. Personalizing Medicine: Systems biology, biomarkers and diagnostics, personalized medicine, targeted therapies, genomics, and combination devices.
• 5. Wellness: Healthful foods and eating; prevention of sickness; corporate takeover of prevention (wellness tied to healthcare), uptake of personal genomics and social networking for wellness.
• 6. Emerging Technologies: Stem cells and regenerative medicine, nanomedicine, RNAi, whole genome scanning and implantable sensors
• 7. Politics and Policy: Healthcare, U.S. Food and Drug Adminstration, and Centers for Medicare & Medicaid Services, what the new administration portends, patent reform.
• 8. Agbio/Biofuels/Industrial Biotech/Cleantech: Next generation biofuels, feedstocks, enzymes and crops. The publication also includes a detailed analysis and charts on:
• 9. International: Profiles and initiatives of the expanding life sciences industry in Canada, Europe, China, India, Malaysia, Latin America, Middle East.
• 10. M&A/Partnering: Dealmaking around the globe.
• 11. Finance and Capital Markets: Performance of biotechnology companies on the capital markets and analysis of 2008 fundraising.

• Total Global Industry Financings
  • By Public Companies
  • By Private Companies
  • By Therapeutic Class
• Industry Market Cap
• Global Industry Financials
  • Revenues
  • Research and Development
  • Profit (Loss)
  • Cash and Cash Equivalents
• 2008 Partnering deals
• 2008 Mergers & Acquisitions

PLEASE NOTE: THIS IS A SPECIAL PRE-PUBLICATION PRICE FOR A PDF VERSION OF BIOTECH 2009 - LIFE SCIENCES: NAVIGATING THE SEA CHANGE. THIS FILE IS EXPECTED BE AVAILABLE FOR DOWNLOAD FEBRUARY 11, 2009.